

Chugai Pharma U.K. Ltd. and Chugai Pharma Europe Ltd. believe it is important to be transparent regarding interactions with Health Care Professionals and Health Care Organisations.

- Patients benefit from the collaboration between Health Care Professionals and the pharmaceutical industry through the development and appropriate use of innovative treatments that aim to improve patient care.
- Health Care Professionals and pharmaceutical companies regularly work together from early scientific research and clinical trial programmes to the use of medicines in the patient pathway.
- As an integral part of the medicines development process it is entirely appropriate that fees are paid to Health Care Professionals to reimburse them for their time and expertise.
- The pharmaceutical industry is committed to ensuring the transparency of relationships with Health Care Professionals. Across Europe the industry has announced its intention to disclose payments to Health Care Professionals at an individual level by 2016 for payments made in 2015 onwards.
- As part of this journey, in 2013, ABPI member companies took the early step of disclosing the total figure paid to all Health Care Professionals during 2013, plus the number of Health Care Professionals that received payments (<http://www.abpi.org.uk>).
- From 2015 all payments to healthcare professionals, healthcare organisations and patient organisations will be disclosed the following year at an individual level wherever possible. Payments to healthcare organisations and patient organisations will be disclosed at an individual level without the requirement for consent. Payments to healthcare professionals will be disclosed at an individual level if the company has received consent from the healthcare professional to do so. If this has not been given then disclosure will be in an aggregated form.
- Payments made to healthcare professionals and healthcare organisations will be disclosed via central portals organised and managed by The Irish Pharmaceutical Healthcare Association (IPHA) and The Association of the British Pharmaceutical Industry (ABPI). These payments will be available for public scrutiny from July 1st 2016 and this page will be updated nearer the time to provide more information.

You can find information regarding:

1. [Support and interactions with Patient Groups](#)
2. [Joint Working arrangements](#)

The amount indicated represent spend in the UK and Ireland for the whole of 2015. The data has been sourced from all Chugai businesses. The amounts indicated excludes money spent by our partners where we co-promote products. The amounts shown are inclusive of VAT and taxes where this is applicable.

For further information please contact disclosure@chugai-pharm.co.uk.

Roche Products Limited and Chugai Pharma U.K. Ltd. have in place a co-promotion agreement for a Prescription Only Medicine (POM). To ensure both companies adhere with the ABPI requirements, each company will independently disclose payments associated with this co-promotion. Further information will be added before July 2016 to provide more information including a link to business partner information. Chugai Pharma U.K. Ltd. have distribution agreements with business partners based outside the UK. These business partners are responsible for the disclosure of any payments made by them.

1. Interactions with Patient Organisations:

Listed on this page you will find all financial interactions that Chugai Pharma U.K. Ltd. and Chugai Pharma Europe Ltd. has had with Patient Organisations during 2015. This includes financial donations to help with the service provided to patients, carers and family members. Chugai has made every effort to ensure the accuracy of this data.

Name Of Patient Organisation	Nature of interaction	Value of support
Transverse Myelitis Society	To support development of a newsletter and patient organisation website to allow the public to be aware of a clinical trial (SAKuraSky). This support was approved by the MHRA and received ethics committee approval. For more information go to http://www.myelitis.org.uk/ . This funding was organised by Chugai Pharma Europe Ltd. as part of a research and development programme (http://www.chugai.co.uk/)	£15,000
Myeloma UK	Travel costs for a representative of Myeloma UK to attend an advisory board in London on 24 th July 2015 with regards to a future product in myeloma and for Chugai Pharma U.K. Ltd. to understand unmet clinical need and future implications and NHS requirements	£257.36
Total		£15,257.36

Joint Working:

Joint Working describes situations where, for the benefit of patients, NHS and industry organisations pool skills, experience and/or resources for the joint development and implementation of patient-centred projects and share a commitment to successful delivery. Many such projects have been successfully implemented, benefiting patients across the UK.

Chugai Pharma U.K. Ltd. will comply with Joint Working policies as defined by the ABPI in all discussions and arrangements.

Name of Joint Working Project	No joint working agreements were discussed or undertaken in 2015
--------------------------------------	--